{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":14,"youtube":8,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05587296\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"OASIS-4","nct_id":"NCT05587296","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oasis-4-nct05587296. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"OASIS-4","arms":[{"description":"Participants will receive 120 mg elinzanetant orally once daily.","label":"Elinzanetant (BAY3427080)","type":"EXPERIMENTAL"},{"description":"Participants will receive matching placebo orally once daily for 12 weeks, followed by 120 mg elinzanetant orally once daily","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-06-05","type":"ESTIMATED"},"conditions":["Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","Hot Flashes"],"enrollment":{"count":474,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Elinzanetant (BAY3427080)","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-07-09","lead_sponsor":"Bayer","official_title":"A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 3.5 Years in Women With Hormone-receptor Positive Breast Cancer:","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-01-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])","timeFrame":"Baseline to Week 4"},{"measure":"Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)","timeFrame":"Baseline to Week 12"}],"references":[{"citation":"Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2.","pmid":"40454634","type":"DERIVED"}],"start_date":{"date":"2022-10-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05587296"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oasis-4-nct05587296"}